Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 3344  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 »   Next article
 »   Previous article
 »   Table of Contents

 Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded9    
    Comments [Add]    

Recommend this journal


Year : 2021  |  Volume : 69  |  Issue : 1  |  Page : 115--118

Preliminary Study of hsa-mir-626 Change in the Cerebrospinal Fluid in Parkinson's Disease

1 Department of Neurology, The Second Xiangya Hospital, Changsha, China
2 State Key Laboratory of Medical Genetics, Changsha, China
3 State Key Laboratory of Medical Genetics; Department of Neurology, Xiangya Hospital, Central South University, Changsha, China

Correspondence Address:
Chun-Yu Wang
Department of Neurology, The Second Xiangya Hospital, Central South University, 139 # The People Road, Changsha - 410 011
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0028-3886.310102

Rights and Permissions

Context: A host of microRNAs have been reported to suppress tumor growth, invasion, and metastasis and play roles in neurodegeneration disorders. Moreover, microRNA changes are found in the peripheral blood, cerebrospinal fluid (CSF), and brain tissues of central nervous system diseases, including glioma, Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis, and depression. Compared with other body fluids, CSF can reflect the brain pathological processes more accurately. Aims: To understand whether microRNA expression may be misregulated in patients with PD, and further discover potential diagnostic biomarkers and promising therapeutic targets for PD. Materials and Methods: Here, through real-time reverse-transcription polymerase chain reaction (RT-PCR), we compared CSF microRNA from 15 PD patients, 11 AD patients, and 16 controls with other neurologic disorders, such as encephalitis and Guillain–Barre syndrome. Results: Finally, we identified hsa-miR-626 changes in the CSF of PD patients. The mean expression level of hsa-miR-626 was significantly reduced in the CSF of PD patients compared with AD patients and controls. Conclusions: Our approach provides a preliminary research for identifying biomarkers in the CSF that could be used for the detection, diagnosis, and monitoring of PD.


Print this article     Email this article

Online since 20th March '04
Published by Wolters Kluwer - Medknow